LYPHOMED's $39.5 MIL. ACQUISITION OF INVENEX LABS WILL DOUBLE SIZE OF FIRM; ANNUAL SALES FROM MERGED INJECTABLE GENERIC AND NUTRIONAL BUSINESSES TOP $60 MIL.